Abstract: N-chloroacetylglutamine is produced by reacting chloroacetyl chloride with an alkaline aqueous solution of glutamine the presence of a water-immiscible organic solvent, separating an aqueous layer by liquid-liquid separation, and crystallizing N-chloroacetyl-glutamine from the aqueous layer under acidic conditions. N-Chloroacetyl-glutamine useful as an intermediate for producing glycyl-L-glutamine which has higher stability than L-glutamine and is used as a component of an infusion solution can be obtained with high efficiency at low cost.

Abstract: The present invention relates to a process for producing 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid compounds or salts thereof represented by the following formula (II): ##STR1## wherein R.sup.1, R.sup.2 and R.sup.3 independently represent hydrogen, hydroxy or lower alkoxy, and R.sup.4 represent hydrogen, lower alkyl, aryl or aralkyl, the process comprising, allowing phenylalanine compounds to react with formaldehyde or paraformaldehyde in the presence of sulfuric acid or hydrobromic acid, the phenylalanine compounds being represented by the following formula (I): ##STR2## wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 have the same meaning as defined above.

Abstract: In the formulae, R.sup.1, R.sup.2, and R.sup.3 independently represent lower alkyl or aryl, and R.sup.4 represents lower alkyl.The present invention relates to a process for producing an indolocarbazole derivative represented by Formula (II), comprising the acidic treatment of a silylated indolocarbazole derivative represented by Formula (VI).

Abstract: Disclosed is a process for producing alanylglutamine, which comprises reacting an N-(2-substituted)-propionylglutamine compound represented by the formula (I): ##STR1## where X represents halogen, alkylsulfonyloxy, or substituted or unsubstituted arylsulfonyloxy, with ammonia at a temperature of 60.degree. C. or below.in accordance with the present invention, highly purified alanylglutamine can be produced in a high yield, without racemization.

Abstract: Disclosed is a process for producing alanylglutamine, which comprises reacting an N-(2-substituted)-propionylglutamine compound represented by the formula (I): ##STR1## where X represents halogen, alkylsulfonyloxy, or substituted or unsubstituted arylsulfonyloxy, with ammonia at a temperature of 60.degree. C. or below.In accordance with the present invention, highly purified alanylglutamine can be produced in a high yield, without racemization.

Abstract: It has been found that aluminum, which is considered as to cause various diseases such as dialysis dementia, bone diseases, hypochromic anemia and Alzheimer's disease, would be eluted into a conventional albumin preparation preserved in a hard glass container, which increases the aluminum concentration of the preparation. According to the present invention, it has been found that the substitution of the conventional hard glass container with a soft glass container dealkalized by, for example, treatment with sulfurous acid gas or ammonium sulfate solution for preserving an albumin preparation can make it possible to prevent the elution of aluminum from the container, thus giving a highly safe albumin preparation which can be maintained with an extremely low aluminum concentration over a long period of time.

Abstract: An indole derivative represented by formula (I): ##STR1## wherein R.sup.1 is a lower alkoxymethyl group or a formyl group, R.sup.2 is a lower alkyl group, R.sup.3 is a hydrogen atom or a lower alkyl group and R.sup.4 is a hydrogen atom or a lower alkyl group, which is useful as an intermediate for the synthesis of a compound, 5-aziridino-3-hydroxymethyl-l-methyl-2- (1H-indole-4,7-dione)prop-.beta.-ene-.alpha.-ol, which has antitumor activity.

Abstract: An albumin preparation having a polymer content of not more than 3% by weight based on the serum albumin content and an .alpha..sub.1 -AGP content of not more than a detectable limit based on the serum albumin content, which is prepared by removing a polymer-forming factor from an albumin aqueous solution by, for example, ion exchange separation or affinity chromatography, and subjecting the solution to a heat treatment.

Abstract: Derivatives of the antibiotic XK-62-2 are prepared by chemically modifying the antibiotic XK-62-2. An example of one such derivative is 1-N-[L-(-)-.alpha.-hydroxy-.gamma.-aminobutyryl]XK-62-2.

Abstract: New 3"-N-demethyl- and 3"-N, 6'-N-didemethyl-1-.alpha.-hydroxy-.omega.-aminoacyl derivatives of the antibiotic XK-62-2, their pharmaceutically-acceptable acid addition salts, and a process for preparing the same are disclosed.

Abstract: 1-N-(.alpha.-Hydroxy-.beta.-aminopropionyl) XK-62-2 is produced by chemically modifying the antibiotic XK-62-2 to introduce an .beta.-hydroxy-.beta.-aminopropionyl group to the amino group bonded to the carbon atom at the 1-position. The derivative is useful as an antibacterial agent.

Abstract: Derivatives of the antibiotic XK-62-2 are prepared by chemically modifying the antibiotic XK-62-2. An example of one such derivative is 1-N-[L-(-)-.alpha.-hydroxy-.gamma.-aminobutyryl] XK-62-2.

Abstract: New 3"-N-demethyl- and 3"-N, 6'-N-didemethyl-1-.alpha.-hydroxy-.omega.-aminoacyl derivatives of the antibiotic XK-62-2, their pharmaceutically-acceptable acid addition salts, and a process for preparing the same are disclosed.

Abstract: New derivatives of an antibiotic XK-62-2 are produced by chemically modifying the antibiotic XK-62-2. The new derivatives are 1-N-(.alpha.-hydroxy-.delta.-aminovaleryl)XK-62-2 and 1-N-(.alpha.-hydroxy-.epsilon.-aminocaproyl)XK-62-2 as well as acid addition salts thereof.

Abstract: 1-N-[L-(-)-.alpha.-hydroxy-.gamma.-aminobutyryl]XK-62-2 is produced by chemically modifying the antibiotic XK-62-2.